← Back to Search

Repetitive Transcranial Magnetic Stimulation

rTMS for Schizophrenia

N/A
Recruiting
Led By Xiaoming Du, PhD
Research Sponsored by University of Maryland, Baltimore
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 weeks
Awards & highlights

Summary

This trial will study how rTMS affects patients with SSD, measuring biomarkers before and after to assess the effects.

Who is the study for?
This trial is for men and women aged 18-65 with schizophrenia-spectrum disorder who can consent to participate. Excluded are those with major medical conditions affecting the brain, high clozapine doses, failed TMS screening, significant head injury or surgery, pregnancy without contraception, metal implants near the head, seizure history, or recent substance abuse.
What is being tested?
The study tests active versus sham (fake) repetitive transcranial magnetic stimulation (rTMS) on patients with schizophrenia. It aims to see how rTMS affects certain biomarkers related to the disorder by comparing results before and after treatment in separate sessions.
What are the potential side effects?
While not explicitly listed here, common side effects of rTMS may include headaches or discomfort at the stimulation site. More serious but rare risks involve seizures or hearing loss if proper ear protection isn't used during treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change of mismatch negativity (MMN) from electroencephalography (EEG) signals by active and sham rTMS
Change of resting-state functional connectivity (rsFC) by active and sham rTMS

Trial Design

2Treatment groups
Experimental Treatment
Group I: Sham rTMS first and active rTMS secondExperimental Treatment1 Intervention
Participants in this arm will receive sham rTMS in one visit first, then receive active rTMS in another visit.
Group II: Active rTMS first and sham rTMS secondExperimental Treatment1 Intervention
Participants in this arm will receive active rTMS in one visit first, then receive sham rTMS in another visit.

Find a Location

Who is running the clinical trial?

University of Maryland, BaltimoreLead Sponsor
705 Previous Clinical Trials
378,400 Total Patients Enrolled
66 Trials studying Schizophrenia
10,207 Patients Enrolled for Schizophrenia
Xiaoming Du, PhDPrincipal InvestigatorUniversity of Maryland, Baltimore
3 Previous Clinical Trials
310 Total Patients Enrolled
3 Trials studying Schizophrenia
310 Patients Enrolled for Schizophrenia

Media Library

rTMS (Repetitive Transcranial Magnetic Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT05660018 — N/A
Schizophrenia Research Study Groups: Sham rTMS first and active rTMS second, Active rTMS first and sham rTMS second
Schizophrenia Clinical Trial 2023: rTMS Highlights & Side Effects. Trial Name: NCT05660018 — N/A
rTMS (Repetitive Transcranial Magnetic Stimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05660018 — N/A
~39 spots leftby Dec 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top